MII VS Onkologie Systemische Therapie Substanzen (UNII) - MII IG Kerndatensatz-Modul Onkologie v2027.0.0-ballot.1

MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 - Germany

This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

ValueSet: MII VS Onkologie Systemische Therapie Substanzen (UNII)

Official URL: https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-unii				Version: 2027.0.0-ballot.1
Active as of 2026-09-15				Computable Name: MII_VS_Onko_Systemische_Therapie_Substanzen_UNII

UNII-Codes für Substanzen der systemischen Therapie ohne ATC-Code. Ergänzung zum ATC-basierten Haupt-ValueSet für neuere und experimentelle onkologische Wirkstoffe.

References

MII PR Onkologie Systemische Therapie Medikation

Logical Definition (CLD)

Profiles: Shareable ValueSet, CRMI Shareable ValueSet, CRMI Publishable ValueSet, CRMI Computable ValueSet

Include these codes as defined in http://fdasis.nlm.nih.gov version Not Stated (use latest from terminology server)

Code	Display
T66ES73M18	ALISERTIB
F333OQQ9UV	ASUNERCEPT
31M3WLJ3KG	BELVARAFENIB
0ICW2LX8AS	BEMCENTINIB
0ZM2Z182GD	BUPARLISIB
85RE35306Z	CERALASERTIB
4EDF46E4GI	CILENGITIDE
923X28214S	CRENIGACESTAT
LQF7I567TQ	CRENOLANIB
N9B0H171MJ	DERAZANTINIB
SJ82PK3HWA	EFTILAGIMOD ALFA
SMA5ZS5B22	ENSARTINIB
6I3O3W6O3B	ENTOSPLETINIB
UC96G28EQF	ENZASTAURIN
2E8412Y946	GANETESPIB
QSQ883V35U	IDASANUTLIN
F60NE4XB53	IMETELSTAT
L4C1UY2NYH	INAVOLISIB
PP449XA4BH	LUCITANIB
703P9YDP7F	MARIZOMIB
5OGS5K699E	MERESTINIB
6O01GMS00P	MOMELOTINIB
15JL80DG6H	NAPORAFENIB
KE7K32EME8	NAZARTINIB
JTZ51LIXN4	NEMTABRUTINIB
MTM792B442	OLAPTESED PEGOL
S3AZD8D215	PEVONEDISTAT
JNA39I7ZVB	PIRTOBRUTINIB
08O3FQ4UNP	REPOTRECTINIB
15KFN616FK	RINETERKIB
67DOW7F9GL	RIGOSERTIB
0282IF4JC8	SIREMADLIN
G287IC9MH3	TILSOTOLIMOD
MAT637500A	TIPIFARNIB
LXG44NDL2T	TIRABRUTINIB
PJ4H73IL17	TIVANTINIB
ZN90E4027M	TOVORAFENIB
X8Y5U6NC7E	TREBANANIB
U36PGF65JH	UMIROLIMUS
6EM57086EA	VOLASERTIB
H4GXR80IZE	ZOTAROLIMUS
7OSV6M6T4D	ALNUCTAMAB
6HP0354G04	AMATUXIMAB
PRC974M49B	BALIXAFORTIDE
Q16CT95N25	BAVITUXIMAB
RJW23BQ0KW	BEMARITUZUMAB
LYK98WP91F	CETRELIMAB
RR5U4UFJ8L	CUSATUZUMAB
2OQ3OPV2F8	DARLEUKIN
GD2OWY1DTK	DATOPOTAMAB DERUXTECAN
W984C353CG	DEPATUXIZUMAB
RB3U3A1S27	DISITAMAB VEDOTIN
L0HR9A577V	ELRANATAMAB
DGK38A42AE	ELSILIMOMAB
VE267FC2UB	FIGITUMUMAB
S9OX9692ZB	GALIXIMAB
85V55ZLV2Z	GATIPOTUZUMAB
4B57CWT710	GEBASAXTUREV
28P3DU6DB3	GIREDESTRANT
539B57DFJF	GIRENTUXIMAB
06P3KLK2J8	GLOFITAMAB
8V66F27X44	IBERDOMIDE
XGL4M23834	INDATUXIMAB RAVTANSINE
GO90DFK14U	INOLIMOMAB
0H2XLR2IKW	LEMZOPARLIMAB
NYM5HO7I39	LONCASTUXIMAB
7K5O7P6QIU	LONCASTUXIMAB TESIRINE
90YIEHRFJ9	MAGROLIMAB
98DE7VN88D	MIRVETUXIMAB SORAVTANSINE
DA9G065962	MOTIXAFORTIDE
ND296JF21I	NIDANILIMAB
W2OR26S7UE	NISEVOKITUG
6HXC0O6JMV	ONFEKAFUSP ALFA
S9J80L3D1U	PELAREOREP
IBS1BZ4E4I	PENPULIMAB
4XG66BMN0D	PLOZALIZUMAB
AF75XOF6W3	RELATLIMAB
51WEW898IJ	RILOTUMUMAB
P256HB60FF	ROVALPITUZUMAB TESIRINE
1N3L70MDFX	SERIBANTUMAB
8FU7FQ8UPK	SINTILIMAB
QOG25L6Z8Z	SPARTALIZUMAB
X8JR0I7JE1	TALACOTUZUMAB
6XG22YQM2Z	TIRAGOLUMAB
T41737F88A	TISOTUMAB VEDOTIN
5P637IXG16	TOMUZOTUXIMAB
8JXN261VVA	TORIPALIMAB
230902QLLC	URELUMAB
5XO3JF0FEK	VIBOSTOLIMAB
IZY9ZSI6FI	ZILOVERTAMAB VEDOTIN
94N635564T	HUMAN PARVOVIRUS B19
1Q8D39N37L	AMONAFIDE
XT3Z54Z28A	CAMPTOTHECIN
04079A1RDZ	CYTARABINE
5L84T2Z6NP	DAUNORUBICIN CITRATE
V1JK16Y2JP	DOXIFLURIDINE
2KT4YN1DP7	GUADECITABINE
P88XT4IS4D	PACLITAXEL
Z8R4A37V9Q	ARFOLITIXORIN
BNO1JG5MZC	BEMPEGALDESLEUKIN
4MXU9LJS4Q	LEUCOVORIN SODIUM

Expansion

Expansion from 127.0.0.1 based on codesystem Unique Ingredient Identifier (UNII) version 20250702

This value set contains 101 concepts

System	Code	Display (en)	JSON	XML
`http://fdasis.nlm.nih.gov`	T66ES73M18	ALISERTIB
`http://fdasis.nlm.nih.gov`	F333OQQ9UV	ASUNERCEPT
`http://fdasis.nlm.nih.gov`	31M3WLJ3KG	BELVARAFENIB
`http://fdasis.nlm.nih.gov`	0ICW2LX8AS	BEMCENTINIB
`http://fdasis.nlm.nih.gov`	0ZM2Z182GD	BUPARLISIB
`http://fdasis.nlm.nih.gov`	85RE35306Z	CERALASERTIB
`http://fdasis.nlm.nih.gov`	4EDF46E4GI	CILENGITIDE
`http://fdasis.nlm.nih.gov`	923X28214S	CRENIGACESTAT
`http://fdasis.nlm.nih.gov`	LQF7I567TQ	CRENOLANIB
`http://fdasis.nlm.nih.gov`	N9B0H171MJ	DERAZANTINIB
`http://fdasis.nlm.nih.gov`	SJ82PK3HWA	EFTILAGIMOD ALFA
`http://fdasis.nlm.nih.gov`	SMA5ZS5B22	ENSARTINIB
`http://fdasis.nlm.nih.gov`	6I3O3W6O3B	ENTOSPLETINIB
`http://fdasis.nlm.nih.gov`	UC96G28EQF	ENZASTAURIN
`http://fdasis.nlm.nih.gov`	2E8412Y946	GANETESPIB
`http://fdasis.nlm.nih.gov`	QSQ883V35U	IDASANUTLIN
`http://fdasis.nlm.nih.gov`	F60NE4XB53	IMETELSTAT
`http://fdasis.nlm.nih.gov`	L4C1UY2NYH	INAVOLISIB
`http://fdasis.nlm.nih.gov`	PP449XA4BH	LUCITANIB
`http://fdasis.nlm.nih.gov`	703P9YDP7F	MARIZOMIB
`http://fdasis.nlm.nih.gov`	5OGS5K699E	MERESTINIB
`http://fdasis.nlm.nih.gov`	6O01GMS00P	MOMELOTINIB
`http://fdasis.nlm.nih.gov`	15JL80DG6H	NAPORAFENIB
`http://fdasis.nlm.nih.gov`	KE7K32EME8	NAZARTINIB
`http://fdasis.nlm.nih.gov`	JTZ51LIXN4	NEMTABRUTINIB
`http://fdasis.nlm.nih.gov`	MTM792B442	OLAPTESED PEGOL
`http://fdasis.nlm.nih.gov`	S3AZD8D215	PEVONEDISTAT
`http://fdasis.nlm.nih.gov`	JNA39I7ZVB	PIRTOBRUTINIB
`http://fdasis.nlm.nih.gov`	08O3FQ4UNP	REPOTRECTINIB
`http://fdasis.nlm.nih.gov`	15KFN616FK	RINETERKIB
`http://fdasis.nlm.nih.gov`	67DOW7F9GL	RIGOSERTIB
`http://fdasis.nlm.nih.gov`	0282IF4JC8	SIREMADLIN
`http://fdasis.nlm.nih.gov`	G287IC9MH3	TILSOTOLIMOD
`http://fdasis.nlm.nih.gov`	MAT637500A	TIPIFARNIB
`http://fdasis.nlm.nih.gov`	LXG44NDL2T	TIRABRUTINIB
`http://fdasis.nlm.nih.gov`	PJ4H73IL17	TIVANTINIB
`http://fdasis.nlm.nih.gov`	ZN90E4027M	TOVORAFENIB
`http://fdasis.nlm.nih.gov`	X8Y5U6NC7E	TREBANANIB
`http://fdasis.nlm.nih.gov`	U36PGF65JH	UMIROLIMUS
`http://fdasis.nlm.nih.gov`	6EM57086EA	VOLASERTIB
`http://fdasis.nlm.nih.gov`	H4GXR80IZE	ZOTAROLIMUS
`http://fdasis.nlm.nih.gov`	7OSV6M6T4D	ALNUCTAMAB
`http://fdasis.nlm.nih.gov`	6HP0354G04	AMATUXIMAB
`http://fdasis.nlm.nih.gov`	PRC974M49B	BALIXAFORTIDE
`http://fdasis.nlm.nih.gov`	Q16CT95N25	BAVITUXIMAB
`http://fdasis.nlm.nih.gov`	RJW23BQ0KW	BEMARITUZUMAB
`http://fdasis.nlm.nih.gov`	LYK98WP91F	CETRELIMAB
`http://fdasis.nlm.nih.gov`	RR5U4UFJ8L	CUSATUZUMAB
`http://fdasis.nlm.nih.gov`	2OQ3OPV2F8	DARLEUKIN
`http://fdasis.nlm.nih.gov`	GD2OWY1DTK	DATOPOTAMAB DERUXTECAN
`http://fdasis.nlm.nih.gov`	W984C353CG	DEPATUXIZUMAB
`http://fdasis.nlm.nih.gov`	RB3U3A1S27	DISITAMAB VEDOTIN
`http://fdasis.nlm.nih.gov`	L0HR9A577V	ELRANATAMAB
`http://fdasis.nlm.nih.gov`	DGK38A42AE	ELSILIMOMAB
`http://fdasis.nlm.nih.gov`	VE267FC2UB	FIGITUMUMAB
`http://fdasis.nlm.nih.gov`	S9OX9692ZB	GALIXIMAB
`http://fdasis.nlm.nih.gov`	85V55ZLV2Z	GATIPOTUZUMAB
`http://fdasis.nlm.nih.gov`	4B57CWT710	GEBASAXTUREV
`http://fdasis.nlm.nih.gov`	28P3DU6DB3	GIREDESTRANT
`http://fdasis.nlm.nih.gov`	539B57DFJF	GIRENTUXIMAB
`http://fdasis.nlm.nih.gov`	06P3KLK2J8	GLOFITAMAB
`http://fdasis.nlm.nih.gov`	8V66F27X44	IBERDOMIDE
`http://fdasis.nlm.nih.gov`	XGL4M23834	INDATUXIMAB RAVTANSINE
`http://fdasis.nlm.nih.gov`	GO90DFK14U	INOLIMOMAB
`http://fdasis.nlm.nih.gov`	0H2XLR2IKW	LEMZOPARLIMAB
`http://fdasis.nlm.nih.gov`	NYM5HO7I39	LONCASTUXIMAB
`http://fdasis.nlm.nih.gov`	7K5O7P6QIU	LONCASTUXIMAB TESIRINE
`http://fdasis.nlm.nih.gov`	90YIEHRFJ9	MAGROLIMAB
`http://fdasis.nlm.nih.gov`	98DE7VN88D	MIRVETUXIMAB SORAVTANSINE
`http://fdasis.nlm.nih.gov`	DA9G065962	MOTIXAFORTIDE
`http://fdasis.nlm.nih.gov`	ND296JF21I	NIDANILIMAB
`http://fdasis.nlm.nih.gov`	W2OR26S7UE	NISEVOKITUG
`http://fdasis.nlm.nih.gov`	6HXC0O6JMV	ONFEKAFUSP ALFA
`http://fdasis.nlm.nih.gov`	S9J80L3D1U	PELAREOREP
`http://fdasis.nlm.nih.gov`	IBS1BZ4E4I	PENPULIMAB
`http://fdasis.nlm.nih.gov`	4XG66BMN0D	PLOZALIZUMAB
`http://fdasis.nlm.nih.gov`	AF75XOF6W3	RELATLIMAB
`http://fdasis.nlm.nih.gov`	51WEW898IJ	RILOTUMUMAB
`http://fdasis.nlm.nih.gov`	P256HB60FF	ROVALPITUZUMAB TESIRINE
`http://fdasis.nlm.nih.gov`	1N3L70MDFX	SERIBANTUMAB
`http://fdasis.nlm.nih.gov`	8FU7FQ8UPK	SINTILIMAB
`http://fdasis.nlm.nih.gov`	QOG25L6Z8Z	SPARTALIZUMAB
`http://fdasis.nlm.nih.gov`	X8JR0I7JE1	TALACOTUZUMAB
`http://fdasis.nlm.nih.gov`	6XG22YQM2Z	TIRAGOLUMAB
`http://fdasis.nlm.nih.gov`	T41737F88A	TISOTUMAB VEDOTIN
`http://fdasis.nlm.nih.gov`	5P637IXG16	TOMUZOTUXIMAB
`http://fdasis.nlm.nih.gov`	8JXN261VVA	TORIPALIMAB
`http://fdasis.nlm.nih.gov`	230902QLLC	URELUMAB
`http://fdasis.nlm.nih.gov`	5XO3JF0FEK	VIBOSTOLIMAB
`http://fdasis.nlm.nih.gov`	IZY9ZSI6FI	ZILOVERTAMAB VEDOTIN
`http://fdasis.nlm.nih.gov`	94N635564T	HUMAN PARVOVIRUS B19
`http://fdasis.nlm.nih.gov`	1Q8D39N37L	AMONAFIDE
`http://fdasis.nlm.nih.gov`	XT3Z54Z28A	CAMPTOTHECIN
`http://fdasis.nlm.nih.gov`	04079A1RDZ	CYTARABINE
`http://fdasis.nlm.nih.gov`	5L84T2Z6NP	DAUNORUBICIN CITRATE
`http://fdasis.nlm.nih.gov`	V1JK16Y2JP	DOXIFLURIDINE
`http://fdasis.nlm.nih.gov`	2KT4YN1DP7	GUADECITABINE
`http://fdasis.nlm.nih.gov`	P88XT4IS4D	PACLITAXEL
`http://fdasis.nlm.nih.gov`	Z8R4A37V9Q	ARFOLITIXORIN
`http://fdasis.nlm.nih.gov`	BNO1JG5MZC	BEMPEGALDESLEUKIN
`http://fdasis.nlm.nih.gov`	4MXU9LJS4Q	LEUCOVORIN SODIUM

Description of the above table(s).

IG © 2022+ Medizininformatik Initiative. Package de.medizininformatikinitiative.kerndatensatz.onkologie#2027.0.0-ballot.1 based on FHIR 4.0.1. Generated 2026-09-15
Links: Table of Contents | QA Report | netzwerk-universitaetsmedizin.de | medizininformatik-initiative.de | Legal notice
HL7®, FHIR® and the FHIR flame design are registered trademarks of Health Level Seven International. Their use does not constitute endorsement by HL7.